EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Dengue and severe dengue

Shirin Kalimuddin iD, Po Ying Chia iD, Jenny G Low, Eng Eong Ooi iD

Clinical Microbiology Reviews · 11.12.2025 · 38 (4)

DOI: 10.1128/cmr.00244-24 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, erschienen am 11.12.2025. Verfasst von Shirin Kalimuddin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Singapore General Hospital, Singapore, Singapore. Hauptthemen laut MEDLINE: Dengue Virus, Dengue, Severe Dengue. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 434 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dengue is an acute mosquito-borne viral disease that is highly prevalent throughout the tropical world. The geographic footprint of the four dengue viruses (DENV-1 to -4) that cause this disease and their Aedes mosquito vector is expanding, extending into North America and Mediterranean Europe. Furthermore, although dengue has historically been a disease that disproportionately affects children, changing population demographics and increasing travel to and from the tropics have contributed to a growing incidence in adults. Dengue in adults, particularly older adults, brings fresh and complex challenges to case management. Although dengue is now a vaccine-preventable disease, the efficacy profiles of licensed vaccines as well as those in late-stage clinical development suggest that vaccination alone would not fully retard the global expansion of dengue. Other countermeasures, including antiviral drugs, will be needed. This paper reviews the molecular interplay underlying dengue pathogenesis, including from virological and immunological perspectives, which are foundational for developing antiviral therapies and new vaccines. It also reviews the hurdles facing antiviral development and discusses new insights on dengue immunity that can guide the deployment of imperfect vaccines to begin reversing the global burden of dengue.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dengue VirusDengueSevere DengueHumansDengue VaccinesAnimalsAntiviral Agents

Stichwörter der Autor:innen

adult denguedenguedengue virus (DENV)host factorshost responseimmunitytherapeuticsvaccines

Substanzen

Dengue VaccinesAntiviral Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases, Singapore General Hospital, Singapore, Singapore.
  • Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore.
  • National Center for Infectious Diseases, Singapore, Singapore.
  • Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore.
  • Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore, Singapore.
  • Viral Research and Experimental Medicine Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore.

ORCID-Profile: Shirin Kalimuddin, Po Ying Chia, Eng Eong Ooi

Förderung

  • National Medical Research Council

Zitieren

APA

Kalimuddin, S., Chia, P. Y., Low, J. G., & Ooi, E. E. (2025). Dengue and severe dengue. Clinical Microbiology Reviews, 38(4). https://doi.org/10.1128/cmr.00244-24

Vancouver

Kalimuddin S, Chia PY, Low JG, Ooi EE. Dengue and severe dengue. Clinical Microbiology Reviews. 2025;38(4). doi:10.1128/cmr.00244-24

BibTeX
@article{Kalimuddin2025,
  author = {Kalimuddin, Shirin and Chia, Po Ying and Low, Jenny G and Ooi, Eng Eong},
  title = {Dengue and severe dengue},
  journal = {Clinical Microbiology Reviews},
  year = {2025},
  volume = {38},
  number = {4},
  doi = {10.1128/cmr.00244-24}
}
Kostenlos starten →